Table 9.
Medical cannabis effects on mood disorders at 1, 3, and 12 months in Italian fibromyalgia patients
| Prior MC | With MC | P | Prior MC | With MC | P | Prior MC | With MC | P | |
|---|---|---|---|---|---|---|---|---|---|
| 1 month, 30 patients | 3 months, 18 patients | 12 months, 12 patients | |||||||
| HADS anxiety | |||||||||
| Median | 13 | 11 | >0.01 | 12 | 8.5 | >0.01 | 9 | 7 | >0.01 |
| IQR | 7.5 | 8.25 | 9.25 | 11.5 | 7.25 | 10.5 | |||
| Mean | 13 | 11 | 12 | 8.5 | 9 | 7 | |||
| ± SD | 4.3 | 5.6 | 4.6 | 6.3 | 4.7 | 6.3 | |||
| HADS depression | |||||||||
| Median | 11.5 | 10.5 | >0.01 | 11,5 | 9 | >0.01 | 11 | 7 | >0.01 |
| IQR | 6.75 | 9 | 8.25 | 10 | 6.5 | 10.5 | |||
| Mean | 11.5 | 10.5 | 9 | 8.4 | 11 | 7 | |||
| ± SD | 4.2 | 5.8 | 4.3 | 5.9 | 3.9 | 5.7 | |||
MC medical cannabis, HADS Hospital Anxiety Depression Scale, IQR interquartile range, ± plus/minus, SD standard deviation. Mood disorders were measured with Hospital Anxiety and Depression Scale (HADS) in a cohort of 38 patients with fibromyalgia syndrome treated with medical cannabis at an Italian pain clinic. Wilcoxon signed-rank test was used to evaluate differences between time points